Walleye Trading
MRNS

Walleye Trading’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Walleye Trading’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,227
Closed -$45.9K – 5554
2023
Q4 		$45.9K Sell
4,227
-15,456
-79% -$116K ﹤0.01% 4357
2023
Q3 		$158K Sell
19,683
-25,543
-56% -$212K ﹤0.01% 3744
2023
Q2 		$491K Buy
45,226
+30,083
+199% +$258K ﹤0.01% 2764
2023
Q1 		$104K Buy
+15,143
New +$95K ﹤0.01% 3831
2022
Q4 		– Sell
-17,669
Closed -$117K – 5532
2022
Q3 		$117K Buy
+17,669
New +$109K ﹤0.01% 3992
2022
Q2 		– Sell
-20,587
Closed -$192K – 5812
2022
Q1 		$192K Buy
+20,587
New +$205K ﹤0.01% 3829
2021
Q4 		– Sell
-7,264
Closed -$83.9K – 6021
2021
Q3 		$83K Buy
+7,264
New +$99.9K ﹤0.01% 4459
2016
Q1 		– Sell
-425
Closed -$13K – 5953
2015
Q4 		$13K Hold
425
– – ﹤0.01% 4644
2015
Q3 		$14K Buy
+425
New +$24K ﹤0.01% 4261

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Walleye Trading's MRNS Position: Q1 2024 in Review

Walleye Trading sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2024, closing a stake of 4,227 shares — an estimated $45.9K sold.

Walleye Trading first reported a position in MRNS in Q3 2015 and held it in 9 quarters. The position peaked at $491K in Q2 2023. 112 funds tracked by Wall St. Rank hold MRNS as of Q1 2024.

  • Walleye Trading reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2024 after selling out during the quarter.
  • Walleye Trading sold 4,227 Marinus Pharmaceuticals, Inc shares in Q1 2024, an estimated $45.9K.
  • Walleye Trading first reported a position in Marinus Pharmaceuticals, Inc in Q3 2015 and held it in 9 quarters.
  • Walleye Trading's Marinus Pharmaceuticals, Inc position peaked at $491K in Q2 2023.
  • 112 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.